Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2SD: Switching Second-Line HIV Therapy to Dolutegravir
NCT04229290Phase 4Completed
- Sponsor
- University of Nairobi
- Start
- Feb 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dolutegravir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by University of Nairobi. Started Feb 2020; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04229290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04229290.